Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trial to attack brain cancer. The company's preclinical pipeline products include SL-501, a next generation IL-3R-targeted therapy; SL-101, a single chain monoclonal antibody fragment for the treatment of hematologic cancers; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone646-502-2311
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$900,000.00
Profitability
Miscellaneous
Employees92
Next Earnings Date5/8/2019 (Estimated)
OptionableOptionable
Stemline Therapeutics (NASDAQ:STML) Frequently Asked Questions
What is Stemline Therapeutics' stock symbol?
Stemline Therapeutics trades on the NASDAQ under the ticker symbol "STML."
How were Stemline Therapeutics' earnings last quarter?
Stemline Therapeutics Inc (NASDAQ:STML) announced its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by $0.06. View Stemline Therapeutics' Earnings History.
When is Stemline Therapeutics' next earnings date?
What price target have analysts set for STML?
6 brokers have issued 1 year price targets for Stemline Therapeutics' shares. Their forecasts range from $17.00 to $35.00. On average, they anticipate Stemline Therapeutics' stock price to reach $25.40 in the next twelve months. This suggests a possible upside of 96.9% from the stock's current price. View Analyst Price Targets for Stemline Therapeutics.
What is the consensus analysts' recommendation for Stemline Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stemline Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Stemline Therapeutics.
What are Wall Street analysts saying about Stemline Therapeutics stock?
Here are some recent quotes from research analysts about Stemline Therapeutics stock:
- 1. According to Zacks Investment Research, "Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. " (3/5/2019)
- 2. HC Wainwright analysts commented, "Our 12-month price target is derived from a discounted cash flow based asset value of $1.46B for 15% discount rate and 2% terminal growth rate. The company has approximately 42M shares outstanding after the recent financing. Probabilities of market entry ascribed to SL-401 and SL-701 are 100% and 45%, respectively." (1/25/2019)
Has Stemline Therapeutics been receiving favorable news coverage?
News stories about STML stock have been trending somewhat positive this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Stemline Therapeutics earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Stemline Therapeutics' key competitors?
Some companies that are related to Stemline Therapeutics include Genus (GNS), Clinuvel Pharmaceuticals (CUV), Concordia International (CXR), Mesoblast (MSB), Resverlogix (RVX), Emerald Health Therapeutics (EMH), Theratechnologies (TH), Biotest (BIO), Polynovo (PNV), Oxford BioMedica (OXB), Senesco Technologies (ELOX), Rigel Pharmaceuticals (RIGL), Starpharma (SPL), Neptune Wellness Solutions (NEPT) and IMV (IMV).
What other stocks do shareholders of Stemline Therapeutics own?
Who are Stemline Therapeutics' key executives?
Stemline Therapeutics' management team includes the folowing people:
- Dr. Ivan Bergstein, Founder, Pres, CEO & Chairman (Age 53)
- Mr. David G. Gionco, VP of Fin. & Chief Accounting Officer (Age 59)
- Mr. Kenneth Hoberman, COO & Corp. Sec. (Age 54)
- Robert Francomano, Global Head of Commercial
Who are Stemline Therapeutics' major shareholders?
Stemline Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional investors include Polar Capital LLP (7.24%), BlackRock Inc. (6.49%), FMR LLC (4.55%), Northern Trust Corp (1.24%), Empire Life Investments Inc. (1.18%) and Geode Capital Management LLC (0.98%). Company insiders that own Stemline Therapeutics stock include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Institutional Ownership Trends for Stemline Therapeutics.
Which institutional investors are selling Stemline Therapeutics stock?
STML stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, D. E. Shaw & Co. Inc., Two Sigma Advisers LP, Two Sigma Investments LP, MetLife Investment Advisors LLC, California Public Employees Retirement System and Northern Trust Corp. Company insiders that have sold Stemline Therapeutics company stock in the last year include David Gionco, Ivan Bergstein and Kenneth Hoberman. View Insider Buying and Selling for Stemline Therapeutics.
Which institutional investors are buying Stemline Therapeutics stock?
STML stock was acquired by a variety of institutional investors in the last quarter, including Empire Life Investments Inc., Polar Capital LLP, Millennium Management LLC, BlackRock Inc., Fosun International Ltd, Knott David M, Citigroup Inc. and Telemetry Investments L.L.C.. View Insider Buying and Selling for Stemline Therapeutics.
How do I buy shares of Stemline Therapeutics?
Shares of STML can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Stemline Therapeutics' stock price today?
One share of STML stock can currently be purchased for approximately $12.90.
How big of a company is Stemline Therapeutics?
Stemline Therapeutics has a market capitalization of $410.23 million and generates $900,000.00 in revenue each year. The biopharmaceutical company earns $-67,820,000.00 in net income (profit) each year or ($2.94) on an earnings per share basis. Stemline Therapeutics employs 92 workers across the globe.
What is Stemline Therapeutics' official website?
How can I contact Stemline Therapeutics?
Stemline Therapeutics' mailing address is 750 LEXINGTON AVENUE ELEVENTH FLOOR, NEW YORK NY, 10022. The biopharmaceutical company can be reached via phone at 646-502-2311 or via email at [email protected]
MarketBeat Community Rating for Stemline Therapeutics (NASDAQ STML)
MarketBeat's community ratings are surveys of what our community members think about Stemline Therapeutics and other stocks. Vote "Outperform" if you believe STML will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STML will underperform the S&P 500 over the long term. You may vote once every thirty days.
